MedTrace Logo

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04545762 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-01-14

No results posted yet for this study

Summary

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

Conditions

Interventions

DRUG

Fludarabine

Given intravenously (IV)

DRUG

Cyclophosphamide

Given intravenously (IV)

BIOLOGICAL

anti-CD19 CAR-T cells

Single infusion

Sponsors & Collaborators

  • University of California, Davis

    collaborator OTHER

  • C. Babis Andreadis

    lead OTHER

Principal Investigators

  • Carrie Ho, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-11
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04545762 on ClinicalTrials.gov